Evidence map›Paper›PMID 27087824›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2016

Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System.

Eveline Dischkaln Stolz, Paola Fontoura da Costa, Liciane Fernandes Medeiros, Andressa Souza, Ana Maria Oliveira Battastini, Gilsane Lino von Poser, Carla Bonan, Iraci L S Torres, Stela Maris Kuze Rates

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Antinociceptive Activity of Petroleum Ether Fraction ofBioMed research international · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eveline Dischkaln StolzPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, 90610-000 Porto Alegre, Brazil.
Paola Fontoura da CostaPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, 90610-000 Porto Alegre, Brazil.
Liciane Fernandes MedeirosLaboratório de Farmacologia da Dor e Neuromodulação: Investigações Pré-Clínicas, Departamento de Farmacologia, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, 90046-900 Porto Alegre, Brazil.
Andressa SouzaLaboratório de Farmacologia da Dor e Neuromodulação: Investigações Pré-Clínicas, Departamento de Farmacologia, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, 90046-900 Porto Alegre, Brazil.
Ana Maria Oliveira BattastiniDepartamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, 90035-003 Porto Alegre, Brazil.
Gilsane Lino von PoserPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, 90610-000 Porto Alegre, Brazil.
Carla BonanLaboratório de Neuroquímica e Psicofarmacologia, Faculdade de Biociências, Pontificia Universidade Católica do Rio Grande do Sul, 90619-900 Porto Alegre, Brazil.
Iraci L S TorresLaboratório de Farmacologia da Dor e Neuromodulação: Investigações Pré-Clínicas, Departamento de Farmacologia, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, 90046-900 Porto Alegre, Brazil.
Stela Maris Kuze RatesPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, 90610-000 Porto Alegre, Brazil.
Universidade Federal do Rio Grande do Sul · BRPontifícia Universidade Católica do Rio Grande do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uliginosin B (ULI) is a natural acylphloroglucinol that has been proposed as a new molecular scaffold for developing analgesic and antidepressant drugs. Its effects seem to be due to its ability to increase monoamines in the synaptic cleft by inhibiting their neuronal uptake without binding to their respective transporters, but its exact mode of action is still unknown. Considering the importance of the purinergic system to pain transmission and its modulation by monoamines availability, the aim of this study was to investigate the involvement of adenosinergic signaling in antinociceptive effect of uliginosin B. The selective adenosine A1 receptor antagonist DPCPX and the selective A2A antagonist ZM 241385 prevented the effect of ULI in the hot-plate test in mice. Pretreatment with inhibitors of adenosine reuptake (dipyridamole) or adenosine deaminase (EHNA) did not affect the ULI effect. On the other hand, its effect was completely prevented by an inhibitor of ecto-5'-nucleotidase (AMPCP). This finding was confirmed ex vivo, whereby ULI treatment increased AMP and ATP hydrolysis in spinal cord and cerebral cortex synaptosomes, respectively. Altogether, these data indicate that activation of A1 and A2A receptors and the modulation of ecto-5'-nucleotidase activity contribute to the antinociceptive effect of ULI.

Identifiers

PMID27087824
PMCPMC4819114
OpenAlexW2301596588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.